Enzyme

Human medicines European public assessment report (EPAR): Pylobactell, 13C-urea, Date of authorisation: 07/05/1998, Revision: 12, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024

Human medicines European public assessment report (EPAR): Pylobactell, 13C-urea, Date of authorisation: 07/05/1998, Revision: 12, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Pylobactell, 13C-urea, Date of authorisation: 07/05/1998, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): Evkeeza, evinacumab, Date of authorisation: 17/06/2021, Revision: 3, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024

Human medicines European public assessment report (EPAR): Evkeeza, evinacumab, Date of authorisation: 17/06/2021, Revision: 3, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Evkeeza, evinacumab, Date of authorisation: 17/06/2021, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Pemetrexed Sandoz, pemetrexed, Date of authorisation: 18/09/2015, Revision: 8, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024

Human medicines European public assessment report (EPAR): Pemetrexed Sandoz, pemetrexed, Date of authorisation: 18/09/2015, Revision: 8, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Pemetrexed Sandoz, pemetrexed, Date of authorisation: 18/09/2015, Revision: 8, Status: Authorised

Hate salad or veggies? Just keep eating them. Here’s how our tastebuds adapt to what we eat

Retrieved on: 
Saturday, December 30, 2023

It’s OK if you do, there are plenty of foods in the world, and lots of different ways to prepare them.

Key Points: 
  • It’s OK if you do, there are plenty of foods in the world, and lots of different ways to prepare them.
  • If this idea makes you miserable, fear not, with time and a little effort you can make friends with salad.

Why don’t I like salads?

  • We have evolved to enjoy the sweet or umami (savoury) taste of higher energy foods, because starvation is a more immediate risk than long-term health.
  • Vegetables aren’t particularly high energy but they are jam-packed with dietary fibre, vitamins and minerals, and health-promoting compounds called bioactives.
  • The very things that make plant foods bitter, are the things that make them good for us.
  • Humans have at least 25 different receptors that detect bitterness, and we each have our own genetic combinations.
  • This means we don’t all have the same starting point when it comes to interacting with salads and veggies.
  • But the steps toward learning to like salads and veggies are the same regardless of your starting point.

It takes time

  • Repeat exposures to bitter foods can help us adapt over time.
  • Repeat exposures help our brain learn that bitter vegetables aren’t posions.
  • Read more:
    Food as medicine: why do we need to eat so many vegetables and what does a serve actually look like?

Add masking ingredients

  • The good news is we can use lots of great strategies to mask the bitterness of vegetables, and this positively reinforces our taste training.
  • Salt and fat can reduce the perception of bitterness, so adding seasoning and dressing can help make salads taste better instantly.
  • Adding fruits to salads adds sweetness and juiciness, this can help improve the overall flavour and texture balance, increasing enjoyment.
  • Experimenting with texture (for example chopping vegetables smaller or chunkier) can also help in finding your salad loves.

Challenge your biases

  • Challenging your biases can also help the salad situation.
  • A phenomenon called the “unhealthy-tasty intuition” makes us assume tasty foods aren’t good for us, and that healthy foods will taste bad.

The bottom line


Vegetables are good for us, but we need to be patient and kind with ourselves when we start trying to eat more. Try working with biology and brain, and not against them. And hold back from judging yourself or other people if they don’t like the salads you do. We are all on a different point of our taste-training journey.
Emma Beckett has received funding for research or consulting from Mars Foods, Nutrition Research Australia, NHMRC, ARC, AMP Foundation, Kellogg, and the University of Newcastle. She also works for FOODiQ Global. She is a member of committees/working groups related to nutrition or the Australian Academy of Science, the National Health and Medical Research Council and the Nutrition Society of Australia.

Atavistik Bio Raises Additional $40 Million to Advance Precision Allosteric Small Molecule Therapeutics

Retrieved on: 
Tuesday, December 19, 2023

The financing included existing investors, including The Column Group, Lux Capital, and Nextech Invest, Ltd. Atavistik Bio has raised $100 million in aggregate since its launch in August 2021.

Key Points: 
  • The financing included existing investors, including The Column Group, Lux Capital, and Nextech Invest, Ltd. Atavistik Bio has raised $100 million in aggregate since its launch in August 2021.
  • “We’ve made tremendous progress identifying functional pockets of validated targets and have accelerated the development of precision allosteric therapeutics.
  • “In a short period of time, Atavistik Bio has quickly identified novel allosteric binding pockets in a broad range of targets and built a deep discovery pipeline.
  • Atavistik Bio then applies its state-of-the-art, proprietary AI-enabled drug discovery engine to discover and design small molecules, enabling the rapid advancement of allosteric precision therapeutics.

Codexis Announces Achievement of Gram-scale Synthesis with its ECO Synthesis™ Platform

Retrieved on: 
Wednesday, December 13, 2023

REDWOOD CITY, Calif., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has achieved gram-scale synthesis with its Enzyme-Catalyzed Oligonucleotide (ECO) Synthesis™ technology. This critical technical milestone demonstrates the preparative-scale manufacture of an oligonucleotide, composed of the modified nucleotide building blocks typically used in ribonucleic acid (RNA) therapeutics, under process-like conditions.

Key Points: 
  • REDWOOD CITY, Calif., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has achieved gram-scale synthesis with its Enzyme-Catalyzed Oligonucleotide (ECO) Synthesis™ technology.
  • Successful completion of this milestone enables Codexis engineers to initiate a comprehensive assessment of the purity profile for small interference RNA (siRNA) developed with ECO Synthesis™ technology.
  • “Our scientists have done outstanding work to bring us to this critical milestone for the development of our ECO Synthesis™ technology so rapidly.
  • These distinguished experts were joined by Codexis leadership and discussed the growth of RNAi therapeutics as a modality, the manufacturing landscape and the potential role for Codexis’ ECO Synthesis™ platform to enable commercial-scale production of RNAi therapeutics.

ALS-6000-101 Phase 1a Three-Weekly Dose Escalation Safety Study Data

Retrieved on: 
Wednesday, December 13, 2023

Cohort 7, the final cohort in the three-weekly dose escalation safety study of AVA6000, has completed enrolment and is ongoing

Key Points: 
  • Cohort 7, the final cohort in the three-weekly dose escalation safety study of AVA6000, has completed enrolment and is ongoing
    Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, is pleased to provide detailed pre-clinical, clinical and pharmacokinetic data from the Phase 1a dose escalation study of its lead pre|CISIONTM programme, AVA6000, a tumour activated form of doxorubicin.
  • The key conclusions drawn from the data for AVA6000 to date are:
    The pre|CISIONTM platform targets the release of a chemotherapy to the tumour as intended.
  • A maximum tolerated dose has not been reached in the three-weekly dose escalation study despite dosing approximately 3.5x the normal level of doxorubicin in the highest and final dose cohort in this part of the Phase 1a study.
  • Given the favourable safety data from the three-weekly dosing study, a fortnightly dosing study, which is now screening patients with high FAP levels in the United States, will assist in optimising the schedule and dose for a potentially pivotal Phase 2 study in 2024.

Tome Biosciences Launches with Over $200 Million in Funding to Advance Programmable Genomic Integration Platform

Retrieved on: 
Tuesday, December 12, 2023

Backed by leading biotech investors Andreessen Horowitz, ARCH, GV, Longwood, Polaris and others

Key Points: 
  • Backed by leading biotech investors Andreessen Horowitz, ARCH, GV, Longwood, Polaris and others
    WATERTOWN, Mass., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Tome Biosciences , Inc., the programmable genomic integration company, has launched to usher in a new era of genomic medicines based on programmable genomic integration (PGI).
  • “PGI represents the maturation of editing technologies, breaking current barriers in genomic medicines discovery,” said Rahul Kakkar, MD, President and Chief Executive Officer.
  • “PGI is revolutionary in that we can finally reprogram the human genome with an elegance and efficiency previously unimaginable.
  • Tome has an exclusive license to the core PASTE technology, which includes granted US patent numbers 11,572,556, 11,827,881 and 11,834,658.